M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 7.35 PLN 0.68% Market Closed
Market Cap: 151.4m PLN

Relative Value

The Relative Value of one MOC stock under the Base Case scenario is hidden PLN. Compared to the current market price of 7.35 PLN, Molecure SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
1
Median 3Y
141.5
Median 5Y
98.7
Industry
2.6
Forward
4.7
vs History
vs Industry
Median 3Y
-11.2
Median 5Y
-14.4
Industry
21.7
Forward
-2.8
vs History
vs Industry
Median 3Y
-20
Median 5Y
-26.4
Industry
16.6
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-22.2
Industry
22.5
vs History
68
vs Industry
41
Median 3Y
2
Median 5Y
2.2
Industry
2.3
vs History
69
vs Industry
1
Median 3Y
103.4
Median 5Y
75.3
Industry
2.9
Forward
4.2
vs History
31
vs Industry
0
Median 3Y
-101.7
Median 5Y
-115.3
Industry
5.5
vs History
vs Industry
Median 3Y
-8.6
Median 5Y
-9.7
Industry
13.1
Forward
-7.6
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-9.1
Industry
16.6
Forward
-6.4
vs History
vs Industry
Median 3Y
-13.6
Median 5Y
-21.9
Industry
15.8
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-18
Industry
19.1
vs History
82
vs Industry
30
Median 3Y
2.6
Median 5Y
2.9
Industry
1.9

Multiples Across Competitors

MOC Competitors Multiples
Molecure SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Molecure SA
WSE:MOC
151.4m PLN 29.6 -6.2 -5.7 -5.3
US
Eli Lilly and Co
NYSE:LLY
936.3B USD 15.8 51 34.2 36.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
490.7B USD 5.3 19.6 16 20.7
CH
Roche Holding AG
SIX:ROG
255.9B CHF 4.2 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
210B GBP 4.8 29.7 108 158.1
CH
Novartis AG
SIX:NOVN
201.7B CHF 4.5 17.4 11.1 14.3
US
Merck & Co Inc
NYSE:MRK
242.2B USD 3.8 12.7 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13.2 9.1 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
145B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
PL
M
Molecure SA
WSE:MOC
Average P/E: 23.2
Negative Multiple: -6.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBITDA: 437.4
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.2
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.1
6%
1.8
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
M
Molecure SA
WSE:MOC
Average EV/EBIT: 1 878.3
Negative Multiple: -5.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.7
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.3
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3